Chief Executive Officer, Antion Biosciences
Dr Sven Kili is Chief Executive Officer at Antion Biosciences, a Multiplex Cell Engineering company developing ‘Smart-Data’ driven in-vivo allogeneic cell therapies for underserved patients suffering from recalcitrant diseases.
He was previously the Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases where he led teams developing and commercialising Gene Therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo gene therapy to be approved for children with ADA-SCID; Wiskott – Aldrich syndrome (WAS); Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia.
Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development, approval and commercialisation activities of the first combined ATMP product in the EU for MACI®. He and his team also prepared and submitted Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US. Before joining Genzyme, Sven led the cell therapy activities and oversaw all UK & Irish regulatory functions and was the QPPV for pharmacovigilance for the Geistlich Pharma.
Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy in strategic company formation, clinical development, regulatory compliance, value creation, risk management and product safety, product launches and postmarketing activities. He is on the board of CCRM in Canada; Xintela – a Swedish Stem Cell company, the SAB for LGC Corporation and is the chair of the CGTAC as part of the UK BIA and a Board member of the Standards Coordinating Body for Regenerative Medicine and co-chair of the ISCT Business models & Investment committee.
Most recently, Sven received an academic appointment as Chair at UCL for the course “MSc in Manufacture and Commercialisation of Stem Cell and Gene Therapies” where he leads the course steering committee. Additionally, he still maintains his clinical skills in the UK NHS and serves as an ATLS Instructor in his spare time.
BOOK YOUR PLACE NOW
7 October 2021
BOOK YOUR PLACE NOW